prescription digital therapeutics

FDA clears Pear's digital insomnia therapeutic through 510(k), Pre-Cert pilot pathways
By Dave Muoio | 04:53 pm | March 26, 2020
Somryst, a prescription digital therapeutic combining cognitive behavioral therapy and personalized sleep restriction, is the first software product to put the FDA's early Precertification Program framework through its paces. 
Pear Therapeutics acquires new VR therapeutics, licenses CBT, vocal biomarker tech with flurry of new deals
By Dave Muoio | 05:05 pm | January 07, 2020
New agreements with five different tech companies and research organizations aim to expand and flesh out the digital therapeutics maker's product pipeline.